JB Pharma Stock Soars On Drug Approval From USFDA For Anxiety, Depression

On Wednesday, JB Chemicals and Pharmaceuticals stock closed 6.09 per cent higher at Rs 2,813.90 per scrip compared to its previous close of Rs 2,652.45, the stock jumped on account of a USFDA approval.

The company informed in an exchange filing that US FDA has approved the company's Abbreviated New Drug Application (ANDA) for Doxepin Hydrochloride Capsules USP, 10 mg, 25 mg, 50 mg, 75 mg, and 100 mg. 

The drug is a generic version of Sinequan (Pfizer), which is indicated for the treatment of anxiety, depression, and other target symptoms of psychoneurosis. 

Doxepin Hydrochloride Capsules will be manufactured at JB Pharma’s formulation manufacturing facility in Panoli, Gujarat. Doxepin Hydrochloride Capsules had an estimated annual sales of US USD 23.90 million in the United States (IQVIA MAT Jun’ 2023).